Pharmacogenomics (PGx) Market Size, Share, Growth, and Industry Analysis, By Type (Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other), By Application (Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, and Other), and Regional Forecast to 2028

Updated On: 22 April 2024

REPORT OVERVIEW

• 

• Request a Free Sample to learn more about this report

The global pharmacogenomics (PGx) market size was US$ 8569.5 million in 2022. As per our research, the market is expected to reach USD 14590 million by 2028, exhibiting a CAGR of 9.3% during the forecast period. The COVID-19 pandemic has been unprecedented and staggering, with pharmacogenomics (PGx) experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Pharmacogenomics (PGx) is a field that examines how an individual's genetic composition affects their response to medications. By analyzing genetic variations, PGx seeks to personalize drug treatments, enhancing effectiveness and minimizing adverse effects. Genetic testing identifies specific variants linked to drug responses, enabling healthcare professionals to tailor prescriptions and dosages. This approach enhances patient outcomes, aids in drug development, and offers insights into optimal treatment strategies for various conditions.

In practice, PGx considers genetic diversity to determine individual drug reactions. This information guides clinical decisions, such as drug choice and dosage adjustments, leading to more precise and safer treatments. Despite its potential, integrating PGx into healthcare presents challenges in result interpretation, standardization, and implementation, which the medical community continues to address to unlock the full benefits of personalized medicine.

COVID-19 IMPACT: Personalized Medicine to Boost Demand Significantly

COVID-19 had a life changing impact globally. The pharmacogenomics (PGx) market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for pharmacogenomics experienced an increased demand.

The urgency of the pandemic encouraged the scientific community to collaborate and share data more openly. This spirit of collaboration could spill over into pharmacogenomics, encouraging researchers to share insights, findings, and genetic data more effectively, potentially accelerating advancements in the field.

The pandemic underscored the importance of tailoring medical treatments to individual characteristics. As the world searched for effective treatments and vaccines, the concept of personalized medicine gained prominence. The emphasis on individual differences in COVID-19 outcomes and responses further highlighted the potential benefits of pharmacogenomic approaches in guiding treatment decisions. The market is anticipated to boost the pharmacogenomics (PGx) market share following the pandemic.

LATEST TRENDS

"Integration into Clinical Practice to Broaden Market Growth"

Continued efforts to integrate pharmacogenomic testing into routine clinical practice, allowing healthcare providers to make more informed decisions about drug treatments based on individual genetic profiles. Exploration of novel genetic markers associated with drug responses, potentially leading to the discovery of previously unknown factors influencing drug efficacy and safety.

Further incorporation of pharmacogenomic information into drug labeling by regulatory agencies, helping to guide proper dosing and reduce the risk of adverse reactions. Ongoing improvements in genetic sequencing technologies and data analysis methods, enabling faster and more cost-effective genetic testing for pharmacogenomic purposes. These latest developments are anticipated to boost the pharmacogenomics (PGx) market growth.

SEGMENTATION

• 

• Request a Free Sample to learn more about this report

• By Type

Based on type, the market is divided into Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other.

Polymerase Chain Reaction (PCR) holds a major share of the global market.

• By Application

Based on application, the market is bifurcated into Cardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, and Other.

Cardiovascular Diseases as application holds a major share of the global market.

DRIVING FACTORS

"Growing Genetic Knowledge to Boost Market Share"

The expansion of our understanding of the human genome and its role in health and disease has provided a solid foundation for identifying genetic markers associated with drug responses. Rapid advancements in genetic sequencing technology have made it more accessible and affordable to analyze an individual's genetic variations. This has enabled broader implementation of pharmacogenomics testing.

"Drug Development & Safety to Boost Market Size"

Pharmacogenomics helps pharmaceutical companies develop safer and more effective drugs by identifying potential responders and predicting adverse reactions during drug development. Traditional trial-and-error approaches to drug prescribing can be inefficient and risky. Pharmacogenomics reduces the need for trial and error by providing insight into how a patient might respond to a drug. These factors are anticipated to drive the pharmacogenomics (PGx) market  share.

RESTRAINING FACTORS

"Complex Genetic Interactions to Hamper Market Share"

Many traits and responses are influenced by multiple genes, making it difficult to predict outcomes accurately based solely on individual genetic variations. The cost of genetic testing can be a barrier, especially in regions without widespread insurance coverage or where healthcare systems are under-resourced. Genetic information is sensitive and must be handled with care to ensure patient privacy and data security. Concerns about data breaches or misuse can deter individuals from undergoing genetic testing. The factors are anticipated to hinder the growth of the pharmacogenomics (PGx) market share.

REGIONAL INSIGHTS

• 

• Request a Free Sample to learn more about this report

"North America Dominates the Pharmacogenomics (PGx) market"

North America is the major shareholder for the pharmacogenomics (PGx) market share. The region has been a major driver of pharmacogenomics research and implementation due to its robust research funding, advanced healthcare infrastructure, and a large number of biotechnology and pharmaceutical companies. The FDA has shown interest in incorporating PGx information into drug labeling. Canada also has a strong research focus on pharmacogenomics.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Market Players Profiled

• Abbott Laboratories [U.S.]
• Affymetrix, Inc. [U.S.]
• Assurex Health, Inc. [U.S.]
• AstraZeneca [U.S.]
• GeneDx [U.S.]
• Illumina, Inc. [U.S.]
• Laboratory Corporation of America Holdings (LabCorp) [U.S.]
• Myriad Genetics, Inc. [U.S.]
• Pathway Genomics [U.S.]
• Pfizer, Inc. [U.S.]
• QIAGEN, Inc. [U.S.]
• Roche [U.S.]
• Teva Pharmaceutical Industries Ltd. [U.S.]
• Thermo Fisher Scientific [U.S.]
• Transgenomic, Inc. [U.S.]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.